glucocorticoid
glucocorticoid
Overview
Glucocorticoids are a class of steroid hormones and widely used anti-inflammatory and immunosuppressive agents that act primarily through the glucocorticoid receptor. Endogenously, they are central regulators of metabolism, stress responses, and immune homeostasis; pharmacologically, they are among the most important therapies for inflammatory, autoimmune, allergic, and transplant-related conditions. Their effects are pleiotropic: they can suppress proinflammatory cytokine production, alter leukocyte trafficking and activation, and influence tissue repair and metabolic pathways.
In biomedical research, glucocorticoids are studied both as therapeutic agents and as biologically active signals within disease microenvironments. Recent work has highlighted their role in rheumatoid arthritis, Sjögren’s disease, inflammatory bowel and kidney disorders, cancer immunotherapy toxicity, and T-cell differentiation. At the same time, studies continue to examine glucocorticoid-related adverse effects, including infection risk, cardiovascular associations, and steroid resistance, as well as mechanisms of local glucocorticoid metabolism and receptor signaling.
Recent Publications Focus
Below is a summary of the newest research publications targeting glucocorticoid (sorted by publication date).
Recent research demonstrates glucocorticoid's continued role as a cornerstone therapy across multiple autoimmune and inflammatory conditions, though cumulative exposure carries significant safety concerns. In giant cell arteritis, treatment patterns evolved over 2010-2022 with declining high-dose glucocorticoid use, yet mean 2-year cumulative doses remained substantial at 7.6 grams [PMID 42414038]. Importantly, each additional gram of glucocorticoid was associated with increased mortality, and even low cumulative exposure of ≤5 mg/day correlated with higher infection rates and major adverse cardiovascular events [PMID 42414038]. Glucocorticoid-sparing strategies gained traction during this period, with tocilizumab prescriptions rising to over 25% and methotrexate use expanding in this population [PMID 42414038].
Glucocorticoid dosing patterns and safety remain central questions in managing autoimmune conditions. In rheumatoid arthritis, 75% of newly diagnosed patients received glucocorticoids during the first year following treatment initiation, with mean daily doses of 9.3 mg and substantial tapering within the initial disease course [PMID 42283855]. In ANCA-associated vasculitis, low-dose glucocorticoids during maintenance therapy did not reduce major relapse or hospitalization risk [PMID 42342286]. Telitacicept combined with glucocorticoids in IgA nephropathy patients achieved greater proteinuria reduction compared to telitacicept monotherapy at 6 months [PMID 41964393]. Conventionally, glucocorticoid monotherapy demonstrated efficacy in rare conditions, achieving complete remission in IgA1-λ-type proliferative glomerulonephritis with monoclonal immunoglobulin deposits [PMID 41192914].
Novel mechanistic insights reveal glucocorticoid's immunomodulatory effects at the cellular level. A cell-intrinsic glucocorticoid biosynthesis circuit was identified in homeostatic Th17 cells, where glucocorticoid production and glucocorticoid receptor signaling maintained tissue-protective function and prevented pro-inflammatory differentiation [PMID 42285103]. Glucocorticoids combined with anticoagulation modulated neutrophil-driven neuroinflammation and the central NLRP3/NETosis inflammatory process in severe cerebral venous thrombosis [PMID 42050165]. Additionally, herbal combinations enhanced glucocorticoid-associated anti-inflammatory effects in asthma via the cAMP/PKA/CREB signaling pathway [PMID 41690429].
Glucocorticoid-sparing therapeutic strategies have emerged as priority research areas. In chronic graft-versus-host disease, belumosudil, a ROCK2 inhibitor, enabled significant glucocorticoid dose reduction from 0.29 mg/kg/day to 0.02 mg/kg/day while achieving 55.6% overall response rates and a 12-month overall survival of 75% [PMID 42198791]. These advances collectively underscore glucocorticoid's essential but dose-limited role in autoimmune disease management, with ongoing efforts to minimize cumulative exposure while maintaining therapeutic benefit through combination and adjunctive strategies.